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Abstract Age-related macular degeneration (AMD)
is one of the leading causes of blindness in the devel-
oped world. Although effective treatment modalities
such as anti-VEGF treatment have been developed
for neovascular AMD, there is still no effective
treatment for geographical atrophy, and therefore the
most cost-effective management of AMD is to start
with prevention. This review looks at current evi-
dence on preventive measures targeted at AMD.
Modalities reviewed include (1) nutritional supple-
ments such as the Age-Related Eye Disease Study
(AREDS) formula, lutein and zeaxanthin, omega-3
fatty acid, and berry extracts, (2) lifestyle modifica-
tions, including smoking and body-mass-index, and
(3) filtering sunlight, i.e. sunglasses and blue-block-
ing intraocular lenses. In summary, the only proven
effective preventive measures are stopping smoking
and the AREDS formula.
Keywords AREDS  Age-related macular
degeneration  AMD  Vitamin E  Beta-carotene 
Neovascular AMD  Yellow IOL  Sunlight filtration 
Prevention
Introduction
Age-related macular degeneration (AMD) is one of
the leading causes of blindness in developed coun-
tries [1–3]; currently 11.5% of the population in the
United States is affected [1]. The exact pathogenesis
of AMD remains unknown [4], but one of the main
components is thought to be oxidative stress [5, 6]:
the retina, because of its high oxygen concentration
and intense light exposure, is susceptible to damage
by oxidative stress [6]. Early stages of AMD can be
asymptomatic but can cause severe impairment of
central vision in late stages. Details of the most up-to-
date classification of AMD are given in Table 1.
There have been some promising new treatments in
recent years since the emergence of anti-vascular
endothelial growth factor (anti-VEGF) agents, and
numerous pivotal studies have proven their effective-
ness in controlling neovascular AMD [7]. However,
at the moment, costs for these drugs are high and
patients may have to undergo multiple injections.
Taking in consideration the ever-growing popula-
tion, the incidence of AMD will only increase. In the
United States alone, it is thought that the incidence may
double in the next 20 years [1], and so will the resources
and effort spent in the area. Even if anti-VEGF agents
are made cheaper and more available, more and more
patients will have to rely on them, and as a result the
burden on the healthcare system will be increased [8].
It may be more economical to tackle AMD with
prevention. Studies done on AMD prevention usually
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fall into one of three areas: (1) nutritional supplements,
(2) lifestyle modifications, (3) filtering sunlight. It is
vital that ophthalmologists and general practitioners be
aware of the latest and updated evidence. In this article
we hope to provide an overview of current opinions on
the prevention of AMD.
Methods
An evidence-based approach was adopted in the
review process. The literature up to December 2009
was searched for keywords ‘age-related macular
degeneration’, ‘macular’, ‘AMD’, ‘antioxidants’,
‘mineral supplements’, ‘dietary supplements’, and
‘prevention’. We used the databases Medline, The
Cochrane Library, Embase.com, Web of Knowledge,
and Google Scholar. The search was limited to
studies in human subjects, in English. Strength of
evidence and rating of recommendation were
assessed according to the method described previ-
ously [9], and are summarized in Table 3.
Evidence synthesis
Nutritional supplements
Most studies focused on four types of supplements:
1. AREDS or AREDS-like formulas,
2. Lutein and zeaxanthin,
3. Omega-3 fatty acids,
4. Berry extracts.
AREDS or AREDS-like formulas
The Age-Related Eye Disease Study (AREDS) was
designed to investigate whether active treatment with
supplements such as vitamins and minerals can
reduce the risk of advanced AMD. The main
components of the formula were vitamin A (as
beta-carotene), vitamin C, vitamin E, and zinc. These
ingredients were thought to exert a protective effect
on retinal cells by counteracting oxidative stresses
[10–15]. The formula was a type of active treatment
and therefore the dosages of ingredients were much
higher than the Dietary Reference Intake (DRI),
which is a system of nutrition recommendations from
the Institute of Medicine of the USA National
Academy [16]. For instance, the amount of vitamin
C included in the AREDS formula was 500 mg per
day, whereas the DRI for an adult is only 90 mg per
day (a medium-sized orange contains around 70 mg
of vitamin C, and therefore one has to eat almost
seven or eight oranges to obtain 500 mg of vitamin
C). A detailed comparison of nutrient contents
between the AREDS formula and common fruits is
given in Table 2.
Subjects were categorized initially according to
the suggested grading system [17], and then were
asked to take either the supplements or placebo on
twice a day. The progress of 3,640 subjects was
Table 1 Categorization of age-related macular degeneration (AMD) according to the Age-Related Eye Disease Study (AREDS)
guidelines
Brief description Clinical features Visual acuity
Category 1 Free of AMD in both eyes \5 small drusen in one or both eyes 20/32 or better in both eyes
Category 2 Mild to borderline AMD
in one or both eyes
Multiple small or intermediate drusen in one
or both eyes
Pigment abnormalities in one or both eyes
20/32 or better in both eyes
Category 3 Absence of advanced AMD
in both eyes
Intermediate or large drusen
Geographical atrophy
Features not involving central macular
20/32 or better in better eye
Category 4 Advanced AMD in one eye Advanced AMD or geographical atrophy
in worse eye
No such features in better eye
20/32 or better in better eye
Key: Small drusen,\63 lm in diameter (disc diameter around 1500 lm); intermediate drusen, 63–124 lm in diameter; large drusen,
[125 lm in diameter; pigment abnormalities refer to either hyperpigmentation or depigmentation
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monitored for an average of 6.3 years. In essence, the
results showed a 25% reduction in risk of progression
to advanced AMD if recommended doses of antiox-
idants and zinc were taken daily. However, this was
seen in category 3 or 4 patients only, probably
because of the higher natural risk of progression to
advanced AMD. Results were not significant for
category 2 or 1, i.e. those with small drusen only (the
5-year risk of progression to advanced AMD in
category 2 was only 1.3% and in category 1 \1%).
However, in the USA 80% of people over age 70
fall into category 1 or 2, and hence most people
would probably not benefit from the AREDS formula.
Therefore it was only recommended to high-risk
patients (i.e. category 3 or 4). For low risk patients
(i.e. category 1 or 2), recommendation was deferred
until indicated [17].
Potential risks of the AREDS formula include
kidney stones from vitamin C; fatigue, muscle
weakness, decreased thyroid function, and increased
hemorrhagic stroke risk from vitamin E; increased
lung cancer risk in smokers and yellow discoloration
of skin from beta-carotene; and anemia, decreased
serum high-density lipoprotein cholesterol, and stom-
ach upset from zinc [18]. Despite numerous potential
side effects, the only documented statistically signif-
icant ones were increased genitourinary symptoms,
increased self-reported anemia, and yellow discolor-
ation of skin. Although there was an increase in self-
reported anemia, no significant change in blood
hematocrit level was found. Smokers were discour-
aged from taking pills containing beta-carotene, so an
increased risk of lung cancer with beta-carotene was
not addressed in the AREDS, but it has already been
established in two other trials [19, 20]. Nevertheless,
the few side effects were minor and the formula was
otherwise considered safe. In any case, patients
should always be informed of the risks and when
significant contraindications exist (smoking, vascular
diseases, hyperlipidemia, risk of hemorrhage, etc.),
they should be discouraged from taking the formula.
Instead of an active supplementation formula,
some have proposed an enriched diet alone. The
Rotterdam Study investigated the effect of a vitamin-
and mineral-rich diet alone in the prevention of AMD
[21]. In comparison to the AREDS, no active
interventions were given. Baseline dietary content
was assessed, and followed up for possible develop-
ment of AMD. The study found that an above-median
intake of vitamin C and E, beta-carotene, and zinc
was associated with a striking 35% decrease in
incident AMD [21]. They concluded that such a diet
should be recommended to those with early signs of
AMD or those with a strong family history.
A recent meta-analysis carried out by the Cochrane
Collaboration reviewed the evidence and concluded
that both these recommendations were sound but
patients should nevertheless be warned of potential
harmful effects, particularly those who smoke or who
have vascular diseases [22]. Since patients take these
pills on a prophylactic basis, it is undesirable to have
complications arising.
Lutein and zeaxanthin
Also of great interest is the antioxidant balance
among macular pigments, mainly lutein and its
stereo-isomer, zeaxanthin. These carotenoids exist
Table 2 Dosages of the Age-Related Eye Disease Study (AREDS) type formulas compared with common fruit items
Nutrient AREDS [17] DRIa Orangeb Appleb Blueberryb Bananab Mangob Strawberryb Watermelonb
Vitamin Ac (IU) 5000 3000 225 54 22 64 765 18 569
Vitamin C (mg) 500 90 53.2 4.6 0.7 8.7 27.7 13.7 8.1
Vitamin E (mg) 400 15 0.1 0.18 0.23 0.10 1.12 0.1 0.05
Zinc (mg) 80 11 0.07 0.04 0.1 0.15 0.04 0.06 0.1
Copper (mg) 2 0.9 0.045 0.027 0.12 0.078 0.11 0.03 0.042
Lutein/zeaxanthin (lg) None No data 129 29 33 22 0 9 8
a Dietary Reference Intakes from the Institute of Medicine [16]
b Nutrient contents of common fruit items are measured per 100 g
c Vitamin A as beta-carotene
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in high concentrations in the macula, hence its
yellowish color. In vitro studies have shown that
both protect the retina from oxidative stress [23].
These carotenoids act in biological systems as (1) an
important structural molecule in cell membranes, (2)
a short-wavelength light filter, (3) a keeper of the
redox balance, and (4) a modulator in signal trans-
duction pathways [24, 25]. However, the human body
is not capable of lutein synthesis; it can only be
obtained from diet. Hence, supplementing the body
with lutein may offer protection against AMD.
However, these were not included in the AREDS
because neither of the two substances was ready for
manufacturing as a research formula [18].
The Carotenoids in Age-Related Eye Disease
Study (CAREDS) followed 1,787 American women
aged 50–79 for 4–7 years [26]. Subjects were divided
according to their average intake of dietary lutein and
zeaxanthin, but here were no statistical differences
between the amount of lutein and zeaxanthin they
took and the risk of development of AMD.
Conversely, two other studies were in favor of the
hypothesis. The cohort Pathologies Oculaires Lie´es a`
l’Age (POLA) measured actual plasma carotenoids
levels from 899 subjects and correlated them with
risk of AMD. A striking reduction in risk was found
in those with a high plasma level: the odds ratios
were 0.31 and 0.07 for lutein and zeaxanthin,
respectively [27]. This was in agreement with another
similar study in the UK, where a high plasma
zeaxanthin was associated with a 50% reduction in
risk of AMD [28].
The US Food and Drug Administration (FDA)
denied a link between the carotenoids and AMD
protection after reviewing some interventional and
observational randomized studies [29]. In view of the
contradicting results, the National Eye Institute
(Bethesda, Maryland, USA) launched the Age-
Related Eye Disease Study 2 (AREDS2) in autumn
of 2006, hoping to answer this question. As well as
carotenoids, it also studies omega-3 [30, 31]. It also
modifies the original formula by eliminating beta-
carotene, which increases the risk of lung cancer in
smokers. The proposed study end time is late 2012. In
the meantime, no evidence-based conclusion can be
reached.
Although not yet proven for benefits, many
manufacturers have been including lutein and zea-
xanthin in their supplements, many of which are
available over the counter. In 2006, the Council for
Responsible Nutrition (CRN) in Washington DC
reviewed the risk profile of lutein and concluded that
the only documented side effect is yellow discolor-
ation of skin, characterized by high dermal carotei-
noid levels. This condition is reversible and benign
and there were no other adverse events [32]. The
CRN also suggested a daily lutein upper level of
supplementation (ULS) of 20 mg. Lutein and zea-
xanthin carry potential benefits, and have minimal
side effects. For those who are keen and are at risk of
AMD, they may offer some protection.
Omega-3 fatty acids
The role of omega-3 fatty acids in reducing the
incidence of cardiovascular diseases and strokes has
been well established [33]. For instance, the Amer-
ican Heart Association recommends the intake of
omega-3 fatty acids in the form of either fish or fish
oil capsule supplements for cardiovascular benefits
[34]. Recently, its role in AMD has also been
investigated. Docosahexaenoic acid (DHA) is a type
of omega-3 fatty acid present in high concentration in
the photoreceptor segment of the retina. It is
constantly being shed and reformed in the normal
visual cycle, and has been shown to reduce inflam-
mation and regulate autoimmune responses [35–40],
which in turn prevents AMD. Hodge et al. carried out
a meta-analysis and concluded that evidence so far
was inconsistent and not randomized [41]. Larger
randomized controlled trials are needed before con-
clusions can be drawn.
More recently, the US Twin Study of Age-Related
Macular Degeneration (USTS) investigated the rela-
tionship among 681 twins, and found that fish
consumption and omega-3 fatty acid intake reduced
the risk of AMD [42], by an estimated 22% if omega-
3 was high. However, the study was not randomized
and hence its impact is limited.
Because of the potential antithrombotic effect of
fish oil, the risk of hemorrhagic stroke is potentially
increased [43]. Clinical studies have demonstrated
that even with concurrent administration of agents
like warfarin and aspirin, a high dose of fish oil does
not significantly increase the risk of bleeding
[44–46]. Another safety concern is environmental
contaminants such as mercury, which is commonly
76 Int Ophthalmol (2011) 31:73–82
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found in fish; high consumption of fish or fish oil
capsules may pose potential health threats. The FDA
issued an advisory statement recommending that
pregnant women, breast-feeding mothers and children
avoid eating certain types of seafood high in mercury
[47]. The risk is still low and is limited to certain
types of fish such as golden bass, shark, king
mackerel, and swordfish [33]. Fish oil supplements
are generally considered safe because most industrial
purification processes eliminate these toxins [48, 49].
The risk of taking omega-3 fatty acids either from
dietary fish or fish oil supplements is low, and the
potential benefits outweigh the risks. With the proven
cardiovascular benefits, consumption of fish or fish
oil supplements remains a reasonable and safe
recommendation.
Berry extracts
The interest in berry extracts grew from their anti-
oxidant properties. Probably the most notable mem-
ber of the berry family is blueberry, which ranked
first in antioxidant properties among 100 common
food items published by the United States Depart-
ment of Agriculture assays [50]. As far as ophthal-
mology is concerned, its antioxidant strength helps
reduce risk of AMD, and improves night vision.
Many berry extract products claim to protect eyes
from AMD. Another berry, wolfberry, better known
as ‘goji berry’, which has been long used in
Traditional Chinese Medicine (TCM), is also known
for its eye-protecting properties [51].
Anthocyanin is commonly present, and in plant
studies it was found to absorb blue-green light and
protect cells from light stress [52]. Other laboratory
studies have shown that it can theoretically protect
eyes from degenerative diseases like AMD [53–55].
Others also suggested anti-angiogenic and anti-cancer
properties in anthocyanin [53, 56, 57]. However, at
the moment evidence is limited to the laboratory
level. The precise dosage and frequency remains
uncertain, and potential toxicity and long-term side
effects still require exploration.
Currently there are no legal requirements for
quality control of these extracts. Most of these
products need not disclose their exact content and
production method. At the moment, berry extracts
should not be recommended.
Lifestyle modifications
Smoking cessation
The only established causative factor for AMD is
smoking, which has been linked to increased oxida-
tive stress, platelet aggregation, higher fibrinogen
level, and reduced plasma high-density lipoprotein
and antioxidant levels [58–60].
In AREDS Report No. 19, subjects who smoke
were found to have a higher risk of progression to
advanced AMD. For 10 pack-years or higher smok-
ers, the odds ratio for advanced AMD was 1.55 [61].
Results of the US Twin Study showed that current
smokers had a 1.9-fold increased risk of having
AMD, and ex-smokers still had a 1.7-fold increased
risk [42]. If smokers take supplements containing
beta-carotene, the risk of lung cancer is further
increased [19, 20]. All smokers should be advised to
stop.
Body mass index (BMI)
In the AREDS, a higher risk of the geographical
atrophy type of AMD was seen in subjects with
higher BMI [19, 20, 61]. The odds ratio was 1.93 in
obese individuals (obese BMI C 30 kg/m [2], normal
BMI 18.5–24.9 kg/m [2]). Another study by Seddon
et al. also produced similar results [62].
Reducing light exposure
Sunglasses
Some studies have suggested that sunlight exposure
may contribute to AMD [63–73]. The Beaver Dam
Eye Study (BDES) was a population-based cohort
study measuring the amount of sunlight exposure and
incidence of AMD in 2,764 subjects over a 10-year
period [74]. The BDES found that extended sunlight
exposure was associated with higher incidence of
early AMD. However, the protective effect of
sunglasses was only marginal, and the data were
reported on a subjective basis.
More supporting evidence comes from reports on
the incidence of AMD after cataract surgery and
intraocular lens (IOL) implantation [75–77]. Human
crystalline lens turns yellow with age and has been
proven to protect the retina from harmful ultraviolet
Int Ophthalmol (2011) 31:73–82 77
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(UV) blue or blue-green phototoxicity [78, 79]. When
the crystalline lens is removed during surgery, the
implanted IOL does not provide equivalent theoret-
ical protection in vivo [79]. For those who have had
cataract surgery, wearing sunglasses in outdoor areas
may provide protection in this regard.
Spectral filtering IOLs
A theoretical link has been proposed between photo-
toxicity and cataract extraction [80]. Most modern-
day IOLs mimic the crystalline lens in filtering the
harmful UV spectrum of 300–400 nm [78, 81]. The
human crystalline lens turns yellow with age, thereby
blocking blue light (400–500 nm), while IOLs tend to
be transparent [82].
In the Chesapeake Bay Watermen Study, a signif-
icant correlation between blue or visible light expo-
sure and AMD was found [68]. In fact, after cataract
extraction, blue light exposure is greater than at any
other point in life [83].
Among the blue-light blocking properties of modern
IOLs (better known as ‘Yellow IOLs’), transmittance
mimics that of a human adult crystalline lens. One
example is the AcrySof Natural IOL by Alcon (Fort
Worth, Texas, USA), which partially attenuates violet
light (400–440 nm) [84], and blocks 50% of blue light
at 450 nm and 25% at 480 nm [85]. In contrast,
conventional transparent IOLs transmit 90% of light
[400 nm [82]. Therefore these yellow IOLs may
theoretically protect the macula from phototoxicity.
Concerns have been raised that these yellow IOLs
attenuate visual performances under scotopic condi-
tions (defined as lighting levels as experienced on a
moonless night with only starlight), because blue
light, which is more informative in this environment,
is being partially filtered [82]. Furthermore, some
raised the issue of possible differences in color
perception. For instance, driving at night is consid-
ered a mesopic task [86], which refers to lighting
conditions under a quarter of a full moon [87]. Even
under scotopic conditions, contrast sensitivity is
greatest around the 507 nm wavelength, and the
AcrySof Natural IOL transmits 85% of light at this
wavelength, as compared to 90% with conventional
transparent IOLs, and only around 60% in a young
Table 3 Summary of recommendations
Category Study Recommendation Strength of
evidencea
Rating of
recommendationa
Nutritional supplements
AREDS formula AREDS Regular intake may reduce risk of neovascular AMD I B
Cochrane [22] Regular intake may reduce risk of neovascular AMD I A
Lutein and zeaxanthin AREDS2 Not yet available n/a n/a
CAREDS No difference II C
POLA Higher lutein and zeaxanthin reduced risk of AMD II C
Gale et al. [28] Higher lutein and zeaxanthin reduced risk of AMD II C
Omega-3 AREDS2 Not yet available n/a n/a
USTS Higher omega-3 intake reduced risk of AMD II C
Berry extracts None n/a n/a n/a
Life style
Smoking AREDS Smokers had higher risk of AMD I B
USTS Smokers had higher risk of AMD II C
BMI AREDS Higher BMI was associated with higher risk of AMD I B
Sunlight filtering
Sunglasses BDES Benefit of sunglasses use against AMD marginal II C
Yellow IOLs None n/a n/a n/a
n/a data not available, AREDS Age-Related Eye Disease Study [17], AREDS2 Age-Related Eye Disease Study 2 [31], CAREDS
Carotenoids in Age-Related Eye Disease Study [26], POLA ‘Pathologies Oculaires Lie´es a` l’Age’ study [27], USTS United States
Twins Study [42], BDES Beaver Dam Eye Study [66]
a Strength of evidence and rating of recommendation rated according to method described previously [9]
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adult natural crystalline lens [78]. In fact, some
studies even reported increased contrast sensitivity
with the yellow IOLs [88–90].
Cionni used the Farnsworth 100-Hue test in
subjects who had undergone bilateral yellow IOL
implantation, and found no significant changes in
terms of color perception [91]. Comparison was also
made with those who had a yellow IOL implanted in
one eye, and a transparent IOL in the other, and found
no significant alternations [92]. Hence for most
patients a yellow IOL may offer theoretical protec-
tion from AMD.
Summary and conclusions
A systematic review of evidence on the prevention of
age-related macular degeneration was made. A
summary of recommendations is given in Table 3.
The AREDS formula remains the only A-rated
recommendation so far. When dealing with patients,
it is the responsibility of the practitioner to fully
explain the nature of supplements and potential side
effects from long-term regular intake, especially the
increased risk of lung cancer in smokers. Any
misconceptions should be addressed and rectified. It
is also necessary to remind patients that even when
taking the AREDS formula, AMD can still occur.
Patients should be taught self-monitoring methods
and undergo regular fundal examinations by qualified
ophthalmologists. The importance of this cannot be
over-emphasized.
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